Advertisement

Organisation › Details
Relief Therapeutics (Group)
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100TM is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. *
![]() |
Start | 2016-06-01 merged |
![]() |
Industry | drug development |
Industry 2 | aviptadil (NN) | |
![]() |
Person | Selvaraju, Raghuram (Ram) (Relief Therapeutics 202010 Board Chairman) |
Person 2 | Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group) | |
![]() |
Region | Genève (Geneva) GE |
Country | Switzerland | |
Street | 15 Avenue de Sécheron Fondation EIP, Bâtiment F2/F3 | |
City | 1202 Genève GE | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Relief Therapeutics Holding AG. (1/20/21). "Press Release: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil". Geneva & Gundelfingen. | ||
Record changed: 2021-02-01 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Relief Therapeutics (Group)
- [1] Relief Therapeutics Holding AG. (3/22/21). "Press Release: Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine D...
- [2] Relief Therapeutics Holding AG. (3/12/21). "Press Release: Relief Announces CHF 10 Million Private Placement". Geneva....
- [3] Relief Therapeutics Holding AG. (1/20/21). "Press Release: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil". Geneva & Gundelfingen....
- [4] Relief Therapeutics Holding AG. (10/8/20). "Press Release: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer". Geneva....
- [5] PX’Therapeutics S.A.. (10/5/16). "Press Release: PX’Therapeutics and Relief Therapeutics Holding AG Announce a Strategic Collaboration Agreement for the Recombinant Production of Atexakin Alfa". Grenoble & Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top